Dosage and administration
For intravenous infusion: 4 grams in 250 mL of 5% Dextrose Injection, at a rate not exceeding 3 mL per minute. Serum magnesium levels should serve as a guide to continued dosage.
For intravenous infusion: 4 grams in 250 mL of 5% Dextrose Injection, at a rate not exceeding 3 mL per minute. Serum magnesium levels should serve as a guide to continued dosage.
Magnesium Chloride Injection is a sterile solution of Magnesium Chloride Hexahydrate in Water for Injection q.s. Each mL contains Magnesium Chloride Hexahydrate 200 mg, Sodium Chloride 9 mg, Benzyl Alcohol 1% as a preservative, Water for Injection, q.s. pH adjusted with Hydrochloric Acid and/or Sodium Hydroxide. Total osmolarity equivalent to 2.951 mOsm/mL.
Contains 1.97 mEq of Mg++ and Cl- per mL.
The structural formula is MgCl2•6H2O
Magnesium is the second most plentiful cation within cellular fluids. It is an important activator of many enzyme systems and deficits are accompanied by a variety of functional disturbances.
As an electrolyte replenisher in magnesium deficiencies.
Magnesium Chloride Injection should not be administered if there is renal impairment, marked myocardial disease or to comatose patients.
Do not use if a precipitate is present.
The usual precautions for parenteral administration should be observed. Administer with caution if flushing and sweating occurs. A preparation of a calcium salt should be readily available for intravenous injection to counteract potential serious signs of magnesium intoxication. As long as deep tendon reflexes are active it is probable that the patient will not develop respiratory paralysis. Respiration and blood pressure should be carefully observed during and after administration of Magnesium Chloride Injection.
Animal reproduction studies have not been conducted with magnesium chloride. It is also not known whether magnesium chloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Magnesium Chloride should be given to a pregnant woman only if clearly needed.
Flushing, sweating, sharply lowered blood pressure, hypothermia, stupor and ultimately respiratory depression.
For intravenous infusion: 4 grams in 250 mL of 5% Dextrose Injection, at a rate not exceeding 3 mL per minute. Serum magnesium levels should serve as a guide to continued dosage.
1 to 40 grams daily.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
Magnesium Chloride Injection 200 mg/mL (20% w/v).
NDC 67457-134-50
50 mL Multiple-Dose Vial. Individually boxed.
Store at 20° to 25°C (68° to 77°F). [See USP Controlled
Room Temperature.]
Manufactured for:
Mylan Institutional LLC
Morgantown, WV 26505
Manufactured by:
Mylan Institutional
Galway, Ireland
1084L101
Revised: 10/2021
MI:MAGNIJ:R4
NDC 67457-134-50 50 mL
Magnesium
Chloride
Injection
200 mg/mL
(20% w/v)
2.951 mOsm/mL
For Intravenous Use After
Dilution
Rx only Multiple-Dose Vial
Each mL contains: Magnesium
Chloride Hexahydrate 200 mg,
Sodium Chloride 9 mg, Benzyl
Alcohol 1% as a preservative,
Water for Injection q.s. pH adjusted
with Hydrochloric Acid and/or
Sodium Hydroxide.
Total osmolarity equivalent to
2.951 mOsm/mL.
Contains 1.97 mEq of Mg++ and CI¯
per mL.
WARNING: DO NOT USE IF A
PRECIPITATE IS PRESENT.
Store at 20° to 25°C (68° to 77°F).
[See USP Controlled Room
Temperature.]
Usual Dosage: See accompanying
prescribing information.
Manufactured for:
Mylan Institutional LLC
Morgantown, WV 26505 U.S.A.
Manufactured by:
Mylan Institutional
Galway, Ireland
MI:134:1C:R5
Mylan.com

| Class | Version | Type | Effective |
|---|---|---|---|
| MAGNESIUM CATION Pharmacologic Class Indexing | 4 | Indexing - Pharmacologic Class | 20180813 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 67457-134-50 | Magnesium Chloride | 50 mL in 1 VIAL, MULTI-DOSE | INJECTION | 50 | 7 | |
| 67457-134-50 | Magnesium Chloride | 1 in 1 CARTON | INJECTION | 1 | 7 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 67457-134-50 | ML - Milliliter | 67457-134 | f624508d-3fe0-4147-aebc-08cf3ce83d39 | 1 | 2012-07-24 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| MAGNESIUM CHLORIDE | ACTIVE INGREDIENT | 02F3473H9O | 3 | |
| MAGNESIUM CATION | ACTIVE MOIETY | T6V3LHY838 | 3 | |
| BENZYL ALCOHOL | INACTIVE INGREDIENT | LKG8494WBH | 3 | |
| HYDROCHLORIC ACID | INACTIVE INGREDIENT | QTT17582CB | 3 | |
| SODIUM CHLORIDE | INACTIVE INGREDIENT | 451W47IQ8X | 3 | |
| SODIUM HYDROXIDE | INACTIVE INGREDIENT | 55X04QC32I | 3 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 3 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 67457-134 | 67457-134-50 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| MAGNESIUM CHLORIDE | 02F3473H9O | ACTIB |
| SODIUM CHLORIDE | 451W47IQ8X | IACT |
| BENZYL ALCOHOL | LKG8494WBH | IACT |
| WATER | 059QF0KO0R | IACT |
| HYDROCHLORIC ACID | QTT17582CB | IACT |
| SODIUM HYDROXIDE | 55X04QC32I | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION / INTRAVENOUS | 720 mg | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION / INTRAVENOUS | 720 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRAVENOUS | 28773 mg | ||
| BENZYL ALCOHOL | BENZYL ALCOHOL | LKG8494WBH | INJECTION / INTRAVENOUS | 1620 mg | ||
| BENZYL ALCOHOL | BENZYL ALCOHOL | LKG8494WBH | INJECTION / INTRAVENOUS | 1620 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTRAVENOUS | 456 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTRAVENOUS | 456 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRAVENOUS | 28773 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Magnesium Chloride | MAGNESIUM CHLORIDE | Mylan Institutional LLC | 2105d1c1-54ef-4d1a-a63c-b1619e8b50db | 2021-10-15 | Warnings, Adverse reactions | 67457-134-50 67457-134 67457013450 46f389a6-b16b-44af-b468-973805cc3c49 2105d1c1-54ef-4d1a-a63c-b1619e8b50db |
Adverse event summaries are temporarily unavailable. Other product information remains available.